Fidia S.p.A. (BIT:FDA)
0.131
-0.002 (-1.28%)
At close: Dec 5, 2025
Fidia Revenue
Fidia had revenue of 13.59M EUR in the half year ending June 30, 2025, with 51.15% growth. This brings the company's revenue in the last twelve months to 21.13M, down -28.94% year-over-year. In the year 2024, Fidia had annual revenue of 17.53M, down -38.98%.
Revenue (ttm)
21.13M
Revenue Growth
-28.94%
P/S Ratio
0.09
Revenue / Employee
150.93K
Employees
159
Market Cap
1.95M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 17.53M | -11.20M | -38.98% |
| Dec 31, 2023 | 28.74M | 4.07M | 16.52% |
| Dec 31, 2022 | 24.66M | 485.00K | 2.01% |
| Dec 31, 2021 | 24.18M | 2.52M | 11.65% |
| Dec 31, 2020 | 21.65M | -24.55M | -53.13% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Poste Italiane | 13.87B |
| Leonardo S.p.a. | 19.13B |
| Prysmian | 19.49B |
| Fincantieri | 8.84B |
| Iveco Group | 14.55B |
| Interpump Group | 2.07B |
| Maire | 6.91B |
| Webuild | 12.15B |
Fidia News
- 22 hours ago - Praxis' Epilepsy Drug Too Good To Continue, FDA Meeting Up Next - Benzinga
- 23 hours ago - Crude Oil Moves Higher; Domo Shares Plunge - Benzinga
- 23 hours ago - Denali Flags Minimal Delay After FDA Halts Rare Disease Trial Start - Benzinga
- 1 day ago - FDA Warns Against Abbott Glucose Monitor Sensors After Reports Of Over 700 Injuries, 7 Deaths - Benzinga
- 1 day ago - ServiceTitan Posts Upbeat Q3 Results, Joins DigitalBridge, Rubrik, Victoria's Secret And Other Big Stocks Moving Higher On Friday - Benzinga
- 1 day ago - PolyPid Clears a Key FDA Milestone, Reducing Regulatory Risk Ahead of Its Planned NDA Filing ... - GuruFocus
- 1 day ago - Bristol Myers' Cancer Breakthrough Breyanzi Just Won Its Fifth FDA Approval - Benzinga
- 1 day ago - Milestone Pharma Prepares For FDA Decision On CARDAMYST, Stock In Focus - Nasdaq